Patents by Inventor Hanno Langen

Hanno Langen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Biomarkers and methods for progression prediction for chronic kidney disease
    Patent number: 10274502
    Abstract: Subject of the present invention are biomarkers and methods for the identification of an increased risk of the progression of chronic kidney disease (CKD), or for monitoring chronic kidney disease therapy, comprising the detecting the level of one or more of NTpro BNP, EGF, Apo H, GDF-15, and albumin-to-creatinine ratio.
    Type: Grant
    Filed: October 31, 2014
    Date of Patent: April 30, 2019
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Maria Bobadilla, Laura Badi, Guillemette Duchateau-Nguyen, Laurent Essioux, Hanno Langen, Maria Chiara Magnone, Thomas Schindler, Martina Thier, Ivan Formentini, Gonzalo Christian Duran Pacheco, Corinne Solier, Matthias Kretzler, Viji Nair, Ju Wenju
  • BIOMARKERS AND METHODS FOR PROGRESSION PREDICTION FOR CHRONIC KIDNEY DISEASE
    Publication number: 20160320410
    Abstract: Subject of the present invention are biomarkers and methods for the identification of an increased risk of the progression of chronic kidney disease (CKD), or for monitoring chronic kidney disease therapy, comprising the detecting the level of one or more of NTpro BNP, EGF, Apo H, GDF-15, and albumin-to-creatinine ratio.
    Type: Application
    Filed: October 31, 2014
    Publication date: November 3, 2016
    Inventors: Maria BOBADILLA, Laura BADI, Guillemette DUCHATEAU-NGUYEN, Laurent ESSIOUX, Hanno LANGEN, Maria Chiara MAGNONE, Thomas SCHINDLER, Martina THIER, Ivan FORMENTINI, Gonzalo Christian DURAN PACHECO, Corinne SOLIER, Matthias KRETZLER, Viji NAIR, JU Wenju
  • IPP COMPLEX AS MARKER FOR ERLOTINIB TREATMENT
    Publication number: 20120095029
    Abstract: The present invention provides biomarkers which are predictive for the clinical benefit of erlotinib hydrochloride treatment in cancer patients.
    Type: Application
    Filed: October 11, 2011
    Publication date: April 19, 2012
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Angélique Augustin, Guillemette Duchateau-Nguyen, Laurent Essioux, Sabrina Golling, Barbara Klughammer, Jens Lamerz, Hanno Langen, Héléne Meistermann, Stefan Scheiblich, Manuel Tzouros
  • Separation method and device for protein mixtures
    Patent number: 7645369
    Abstract: A separation device and a separation method for biomolecular sample material and in particular protein mixtures. For this purpose a separation element 10 for the two-dimensional and preferable electrophoretic separation of components of the sample material is provided in area 30 of a separation plane. According to the invention it is proposed that the separation element 10 has a channel or transfer structure 14 for the locally resolved discharge of separated sample components in a transport direction that is at right angles to the separation plane onto a support surface 16 that is preferably suitable for mass spectroscopic analyses.
    Type: Grant
    Filed: May 2, 2005
    Date of Patent: January 12, 2010
    Assignee: Roche Diagnositcs Operations, Inc.
    Inventors: Hans-Joachim Hoeltke, Albert Roeder, Alois Rainer, Peter Berndt, Carlo Effenhauser, Hanno Langen, Remo Anton Hochstrasser
  • Cellular retinoic acid binding protein II as a marker for breast cancer
    Patent number: 7579158
    Abstract: The present invention relates to the diagnosis of breast cancer. It discloses the use of protein cellular retinoic acid binding protein II in the diagnosis of breast cancer. It relates to a method for diagnosis of breast cancer from a liquid sample, derived from an individual by measuring cellular retinoic acid binding protein II in said sample. Measurement of cellular retinoic acid binding protein II can, e.g., be used in the early detection or diagnosis of breast cancer.
    Type: Grant
    Filed: December 5, 2005
    Date of Patent: August 25, 2009
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Gabriele Pestlin, Herbert Andres, Peter Berndt, Marie-Luise Hagmann, Johann Karl, Hanno Langen, Werner Zolg
  • Use of protein ASC as a marker for breast cancer
    Patent number: 7566542
    Abstract: The present invention relates to the diagnosis of breast cancer. It discloses the use of protein ASC in the diagnosis of breast cancer. It relates to a method for diagnosis of breast cancer from a liquid sample, derived from an individual by measuring ASC in the sample. Measurement of ASC can, e.g., be used in the early detection or diagnosis of breast cancer.
    Type: Grant
    Filed: April 14, 2006
    Date of Patent: July 28, 2009
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Gabriele Pestlin, Herbert Andres, Peter Berndt, Marie-Luise Hagmann, Johann Karl, Hanno Langen, Werner Zolg
  • Use of protein PSA3 as a marker for colorectal cancer
    Publication number: 20070218510
    Abstract: The present invention relates to the diagnosis of colorectal cancer. It discloses the use of protein proteasome subunit alpha 3 (PSA3) in the diagnosis of colorectal cancer. It relates to a method for diagnosis of colorectal cancer from a liquid sample, derived from an individual by measuring PSA3 in said sample. Measurement of PSA3 can, e.g., be used in the early detection or diagnosis of colorectal cancer.
    Type: Application
    Filed: February 7, 2006
    Publication date: September 20, 2007
    Applicant: Roche Diagnostics Operations, Inc.
    Inventors: Michael Tacke, Peter Berndt, Marie-Luise Hagmann, Johann Karl, Hanno Langen, Stefan Palme, Markus Roessler, Wolfgang Rollinger, Werner Zolg
  • Protein PDX1 as a marker for breast cancer
    Publication number: 20070196844
    Abstract: The present invention relates to the diagnosis of breast cancer. It discloses the use of protein PDX1 (peroxiredoxin 1) in the diagnosis of breast cancer. It relates to a method for diagnosis of breast cancer from a liquid sample, derived from an individual by measuring PDX1 in said sample. Measurement of PDX1 can, e.g., be used in the early detection or diagnosis of breast cancer.
    Type: Application
    Filed: December 14, 2006
    Publication date: August 23, 2007
    Inventors: Gabriele Pestlin, Herbert Andres, Marie-Luise Hagmann, Johann Karl, Michael Thierolf, Werner Zolg, Peter Berndt, Hanno Langen
  • Nicotinamide N-methyltransferase as a marker for colorectal cancer
    Patent number: 7205118
    Abstract: The present invention relates to the diagnosis of colorectal cancer. It discloses the use of the protein nicotinamide N-methyltransferase (NNMT) in the diagnosis of colorectal cancer. It relates to a method for diagnosis of colorectal cancer from a liquid sample, derived from an individual by measuring NNMT in said sample. Measurement of NNMT can, e.g., be used in the early detection or diagnosis of colorectal cancer.
    Type: Grant
    Filed: June 14, 2005
    Date of Patent: April 17, 2007
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Michael Tacke, Peter Berndt, Marie-Luise Hagmann, Johann Karl, Theresa Kott, Hanno Langen, Stefan Palme, Markus Roessler, Wolfgang Rollinger, Werner Zolg
  • In situ polypeptide identification
    Publication number: 20070069122
    Abstract: The invention relates to a method for identifying protein biomarkers directly in a specific region of interest of a tissue which comprises the identification of a mass of interest by analysis of MALDI imaging mass spectrometry results, followed by the identification of the protein represented by said mass of interest by direct elution from the specific region of interest of a tissue, fractionation and tandem mass spectrometry.
    Type: Application
    Filed: June 1, 2006
    Publication date: March 29, 2007
    Inventors: Angelique Augustin, Axel Ducret, Hanno Langen, Helene Meistermann
  • Use of protein ASC as a marker for breast cancer
    Publication number: 20060257952
    Abstract: The present invention relates to the diagnosis of breast cancer. It discloses the use of protein ASC in the diagnosis of breast cancer. It relates to a method for diagnosis of breast cancer from a liquid sample, derived from an individual by measuring ASC in the sample. Measurement of ASC can, e.g., be used in the early detection or diagnosis of breast cancer.
    Type: Application
    Filed: April 14, 2006
    Publication date: November 16, 2006
    Inventors: Gabriele Pestlin, Herbert Andres, Peter Berndt, Marie-Luise Hagmann, Johann Karl, Hanno Langen, Werner Zolg
  • Use of protein UBC13 as a marker for breast cancer
    Publication number: 20060257950
    Abstract: The present invention relates to the diagnosis of breast cancer. It discloses the use of ubiquitin-conjugating enzyme E2N (UBC13) in the diagnosis of breast cancer. It relates to a method for diagnosis of breast cancer from a liquid sample, derived from an individual by measuring UBC13 in the sample. Measurement of UBC13 can, e.g., be used in the early detection or diagnosis of breast cancer.
    Type: Application
    Filed: April 14, 2006
    Publication date: November 16, 2006
    Inventors: Gabriele Pestlin, Herbert Andres, Peter Berndt, Marie-Luise Hagmann, Johann Karl, Hanno Langen, Werner Zolg
  • Use of protein spee as a marker for breast cancer
    Publication number: 20060257951
    Abstract: The present invention relates to the diagnosis of breast cancer. It discloses the use of spermidine synthase (SPEE) in the diagnosis of breast cancer. It relates to a method for diagnosis of breast cancer from a liquid sample, derived from an individual by measuring SPEE in the sample. Measurement of SPEE can, e.g., be used in the early detection or diagnosis of breast cancer.
    Type: Application
    Filed: April 14, 2006
    Publication date: November 16, 2006
    Inventors: Gabriele Pestlin, Peter Berndt, Marie-Luise Hagmann, Johann Karl, Hanno Langen, Norbert Wild, Werner Zolg
  • Use of protein PSE3 as a marker for colorectal cancer
    Publication number: 20060199232
    Abstract: The present invention relates to the diagnosis of colorectal cancer. It discloses the use of protein PSE3 (proteasome activator subunit 3) in the diagnosis of colorectal cancer. It relates to a method for diagnosis of colorectal cancer from a liquid sample, derived from an individual by measuring PSE3 in said sample. Measurement of PSE3 can, e.g., be used in the early detection or diagnosis of colorectal cancer.
    Type: Application
    Filed: February 7, 2006
    Publication date: September 7, 2006
    Applicant: Roche Diagnostics Operations, Inc.
    Inventors: Michael Tacke, Peter Berndt, Marie-Luise Hagmann, Johann Karl, Hanno Langen, Stefan Palme, Markus Roessler, Wolfgang Rollinger, Werner Zolg
  • Use of protein RLA-0 as a marker for colorectal cancer
    Publication number: 20060194266
    Abstract: The present invention relates to the diagnosis of colorectal cancer. It discloses the use of protein RLA-0 (60S acidic ribosomal protein P0) in the diagnosis of colorectal cancer. It relates to a method for diagnosis of colorectal cancer from a liquid sample, derived from an individual by measuring RLA-0 in said sample. Measurement of RLA-0 can, e.g., be used in the early detection or diagnosis of colorectal cancer.
    Type: Application
    Filed: February 7, 2006
    Publication date: August 31, 2006
    Applicant: Roche Diagnostics Operations, Inc.
    Inventors: Michael Tacke, Peter Berndt, Marie-Luise Hagmann, Johann Karl, Hanno Langen, Stefan Palme, Markus Roessler, Wolfgang Rollinger, Werner Zolg
  • Use of protein PLST as a marker for colorectal cancer
    Publication number: 20060188949
    Abstract: The present invention relates to the diagnosis of colorectal cancer. It discloses the use of protein PLST (T-plastin) in the diagnosis of colorectal cancer. It relates to a method for diagnosis of colorectal cancer from a liquid sample, derived from an individual by measuring PLST in said sample. Measurement of PLST can, e.g., be used in the early detection or diagnosis of colorectal cancer.
    Type: Application
    Filed: February 7, 2006
    Publication date: August 24, 2006
    Applicant: Roche Diagnostics Operations, Inc.
    Inventors: Michael Tacke, Peter Berndt, Marie-Luise Hagmann, Johann Karl, Hanno Langen, Stefan Palme, Markus Roessler, Wolfgang Rollinger, Werner Zolg
  • Use of protein spee as a marker for colorectal cancer
    Publication number: 20060188950
    Abstract: The present invention relates to the diagnosis of colorectal cancer. It discloses the use of protein SPEE (sperrnidine synthase) in the diagnosis of colorectal cancer. It relates to a method for diagnosis of colorectal cancer from a liquid sample, derived from an individual by measuring SPEE in said sample. Measurement of SPEE can, e.g., be used in the early detection or diagnosis of colorectal cancer.
    Type: Application
    Filed: February 7, 2006
    Publication date: August 24, 2006
    Applicant: Roche Diagnostics Operations, Inc.
    Inventors: Michael Tacke, Peter Berndt, Marie-Luise Hagmann, Johann Karl, Hanno Langen, Stefan Palme, Markus Roessler, Wolfgang Rollinger, Werner Zolg
  • Use of PRN3/ILEU as a marker for colorectal cancer
    Publication number: 20060177880
    Abstract: The present invention relates to the diagnosis of colorectal cancer. It discloses the use of protein PRN3/ILEU and/or unbound PRN3 in the diagnosis of colorectal cancer. It relates to a method for diagnosis of colorectal cancer from a liquid sample, derived from an individual by measuring PRN3/ILEU and/or unbound PRN3 in said sample. Measurement of PRN3/ILEU and/or unbound PRN3 can, e.g., be used in the early detection or diagnosis of colorectal cancer.
    Type: Application
    Filed: January 20, 2006
    Publication date: August 10, 2006
    Applicant: Roche Diagnostics Operations, Inc.
    Inventors: Michael Tacke, Peter Berndt, Marie-Luise Hagmann, Hanno Langen, Stefan Palme, Markus Roessler, Wolfgang Rollinger, Werner Zolg, Johann Karl
  • Cellular retinoic acid binding protein II as a marker for breast cancer
    Publication number: 20060141543
    Abstract: The present invention relates to the diagnosis of breast cancer. It discloses the use of protein cellular retinoic acid binding protein II in the diagnosis of breast cancer. It relates to a method for diagnosis of breast cancer from a liquid sample, derived from an individual by measuring cellular retinoic acid binding protein II in said sample. Measurement of cellular retinoic acid binding protein II can, e.g., be used in the early detection or diagnosis of breast cancer.
    Type: Application
    Filed: December 5, 2005
    Publication date: June 29, 2006
    Inventors: Gabriele Pestlin, Herbert Andres, Peter Berndt, Marie-Luise Hagmann, Johann Karl, Hanno Langen, Werner Zolg
  • Use of protein MASP as a marker for colorectal cancer
    Publication number: 20060121540
    Abstract: The present invention relates to the diagnosis of colorectal cancer. It discloses the use of protein MASP in the diagnosis of colorectal cancer. It relates to a method for diagnosis of colorectal cancer from a liquid sample, derived from an individual by measuring MASP in said sample. Measurement of MASP can, e.g., be used in the early detection or diagnosis of colorectal cancer.
    Type: Application
    Filed: November 23, 2005
    Publication date: June 8, 2006
    Inventors: Michael Tacke, Peter Berndt, Marie-Luise Hagmann, Johann Karl, Hanno Langen, Stefan Palme, Markus Roessler, Wolfgang Rollinger, Werner Zolg